Clinical trial
NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers.
NCT00318266 · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Other · Completed
Key facts
| NCT number | NCT00318266 |
|---|---|
| Title | NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers. |
| Official title | NMP22 Provides Improved Sensitivity in Detecting Bladder Cancers |
| Lead sponsor | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's, Other |
| Status | Completed |
| Study type | Observational |
| Conditions | Bladder Cancer |
| Intervention type | Device |
| Interventions | Nuclear Matrix Protein 22 Urine sample kit |
| Enrollment | 73 |
| Start date | Jan 1, 2006 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | Apr 26, 2006 |
| Last update posted | Aug 25, 2017 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: